<DOC>
	<DOCNO>NCT01408550</DOCNO>
	<brief_summary>Patients diagnose bullous pemphigoid confirm base investigator national diagnostic criterion . Patients meet inclusion criterion conflict exclusion criterion receive NPB-01 ( intravenous immunoglobulin ) 400mg/kg/day five consecutive day Placebo ( physiological saline ) . Subsequently , efficacy NPB-01 therapy bullous pemphigoid evaluate score use pemphigus disease area index ( PDAI ) pemphigoid activity score involve skin lesion area Number new blister . As safety endpoint , safety NPB-01 investigate occurrence adverse event 57 day start study treatment .</brief_summary>
	<brief_title>Phase III Clinical Trial NPB-01 Patients With Bullous Pemphigoid Unresponsive Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Pemphigoid , Bullous</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Patients corticosteroid 0.4mg/kg/day ( Prednisolone ) inform consent . 2 . Patients continue treatment bullous pemphigoid without add change treatment informed consent . 3 . Patients score use Pemphigus Disease Area Index ( PDAI ) score10 study medication receive . 4 . Patients score use Pemphigus Disease Area Index ( PDAI ) improve study medication receive . 5 . Patients twenty year old informed consent . 6 . Patients hospitalization five consecutive day study medication seven consecutive day administration study medication . 1 . Patients treat plasmapheresis 28 day inform consent . 2 . Patients treat corticosteroid pulse therapy ( methylprednisolone 0.5g/day ) 14 day inform consent . 3 . Patients treat intravenous immunoglobulin 56 day inform consent . 4 . Patients receive adjust increment immunosuppressant 14 day inform consent . 5 . Patients malignancy history disease . 6 . Patients history shock NPB01 . 7 . Patients history hypersensitivity NPB01 . 8 . Patients IgA deficiency . 9 . Patients impaired liver function . 10 . Patients impaired renal function . 11 . Patients cerebro cardiovascular disorder . 12 . Patients high risk thromboembolism . 13 . Patients hemolytic/hemorrhagic anemia . 14 . Patients decrease cardiac function . 15 . Patients decreased platelet .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>IVIG pemphigoid</keyword>
	<keyword>Patients bullous pemphigoid unresponsive corticosteroid</keyword>
</DOC>